The 60,000-square-foot Minakuchi-based facility will establish a new clinical GMP manufacturing and distribution hub for Catalent to support clinical studies. It will also be the largest facility in the company’s Asia Pacific clinical supply network and operate in partnership with Catalent’s existing Japanese clinical supply facility in Kakegawa.
The deal is expected to close on July 1. Financial terms were not disclosed.
The facility will provide customers with access to Catalent’s FashChain supply service, primary and secondary packaging, temperature controlled options for storage and distribution as well as clinical returns and destruction services.
“This new facility provides much-needed capacity as we look to expand our capabilities across the Asia-Pacific region, and follows on from recent expansions and investments we have made in our clinical supply business in China and Singapore,” Ricci Whitlow, president, Catalent Clinical Supply Services, said. “Our strategy has been to build expertise and capacity in this region as demand for local clinical supply services increases, to provide support to customers with global programs, and to meet the growing demand in biologics and cell and gene therapy studies.”